PHIO
Phio Pharmaceuticals Corp.
NASDAQ · Healthcare · Biotechnology · US
$0.87
−0.25%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -82.2%
- EBIT
- -81.0%
- EPS
- +100.0%
- Free cash flow
- -70.9%
- Operating cash flow
- -70.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +46.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -22.2%
- EBIT
- -24.8%
- Net income
- -21.7%
- EPS
- -59.3%
- Free cash flow
- -12.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026